Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Por um escritor misterioso

Last updated 21 setembro 2024

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Brexpiprazole in the Treatment of Major Depressive Disorder - Document - Gale OneFile: Health and Medicine

Journal Digest: Z-Drugs and Dementia; Methotrexate and Schizophrenia; Smartphones and Depression; Brexpiprazole and Sexual Function; E-Cigarettes and Youth; Opioids Deaths and Neighborhoods

PDF) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study

A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder, Acta Neuropsychiatrica

Brexpiprazole - Mechanism of Action and Clinical Application

A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder, Acta Neuropsychiatrica

Frontiers Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder